Clinical Trials Logo

Filter by:
NCT ID: NCT06341777 Completed - Brain Injuries Clinical Trials

Multisensory Telerehabilitation for Visual Field Defects

MUST
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Brain injuries may cause the loss of the ability to see portions of the visual field, the so-called visual field defects (VFDs). VFDs significantly impact the survivors' functional recovery and quality of life, with the majority of patients displaying no spontaneous recovery or being left with residual deficits. Among the available therapies for VFDs, the compensatory scanning training is considered the most promising. Yet, current evidence is insufficient to recommend it in clinical practice, and the scientific community has stressed the need of more high-quality research. The present randomized clinical trial in patients with chronic VFDs caused by brain lesions aims at verifying the feasibility and efficacy of a novel telerehabilitation using a multisensory scanning therapy, by measuring its effects on visual functions and daily activities, and by looking for neural indicators of the therapy-induced improvements.

NCT ID: NCT06339554 Completed - NSCLC Stage IV Clinical Trials

Alectinib-induced Endocrine Toxicity

TOSS-ALK
Start date: October 12, 2018
Phase:
Study type: Observational [Patient Registry]

The experimental Cohort A (male ALK+ ANSCLC patients receiving alectinib), the control Cohort B (female ALK+ ANSCLC patients receiving alectinib) and control Cohort C (male NON-ALK ANSCLC patients) were prospectively evaluated for full hormone assessment of androgen deficiency, AT 8 weeks after treatment start and in case of reported suspected symptoms. Patients with major sexual dysfunctions were referred to endocrinologist.

NCT ID: NCT06338046 Completed - Clinical trials for SKIN ADAPTOGEN AND SEBUM BALANCE EFFICACY

In Vivo Evaluation of NC65 - Vita D-Light SKIN ADAPTOGEN AND SEBUM BALANCE EFFICACY

Shitake
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This double-blind placebo-controlled study intends to confirm skin adaptogen and sebum balance efficacy of the investigational active ingredient NC65 - Vita D-Light, transmitted at 0.5% w/w in a topical cosmetic formulation, on a panel of healthy human subjects. The study is performed by RD Cosmetics - University of Naples Federico II, from October to June 2024. The study involves female and male subjects, scheduled for eligibility screening at the study site. A total of 40 subjects were enrolled, and randomly divided into 2 groups: 20 subjects received the active treatment (cosmetic formulation with 0.5 %w/w NC65 - Vita D-Light) and 20 subjects the placebo one. The cosmetic effectiveness of the products was instrumentally detected, using innovative, non-invasive and worldwide recognized devices for skin analysis, like: - Corneometer CM 825 (C+K electronic GmbH) detects water's content of the stratum corneum. - Tewameter® TM Hex (C+K electronic GmbH) detects the trans-epidermal water loss (TEWL). - Sebumeter SM 815 accurately and reproducibly measures the level of sebum on the skin surface. - Visia VISIA® (Canfield Scientific, Inc.) for skin surface assessment. The monitored skin features parameters will be check after 1 hour (T1h) for the adaptogen test, and after 7, 14 and 28 days (T7 -T14-T28), for the detox test. Panelists will complete the self-assessment questionnaire at the end of the study period (T28).

NCT ID: NCT06337591 Completed - Bladder Cancer Clinical Trials

Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location

VI-RADS
Start date: October 15, 2022
Phase:
Study type: Observational

VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System (VI-RADS) for the assessment of muscle invasion (MI) status in comparison with transurethral resection of bladder cancer (TURB) and to evaluate the diagnostic accuracy of the score according to the specific tumour location.

NCT ID: NCT06337396 Completed - Clinical trials for Neurodevelopmental Disorders

Omic Approaches to Neurodevelopmental Disabilities

Start date: May 5, 2021
Phase: N/A
Study type: Interventional

to bridge the gap between the molecular structure of CNV and the effect on the phenotype, considering NDDs as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. This holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction

NCT ID: NCT06334744 Completed - Clinical trials for Oncologic Complications

Ambispective Observational Multicenter Study on the Efficacy of the Third Dose of Vaccine Anti COVID-19 in Patients Suffering From Solid Tumors Undergoing Oncological Treatment Active.

Start date: November 17, 2021
Phase:
Study type: Observational

To evaluate the serum neutralizing antibody titre in cancer patients undergoing active treatment against variants (VOC) before and after the third dose of BNT162b2 COVID-19 vaccine.

NCT ID: NCT06331975 Completed - Clinical trials for Non Small Cell Lung Cancer

Radiomics and Radiogenomics of Non-small Cell Lung Cancer

Start date: June 12, 2018
Phase: N/A
Study type: Interventional

In this study, the radiomic characteristics and a broad range of genetic aberrations in lung adenocarcinomas will be evaluated. Investigators will assess changes in the radiomic and genetic profiles during targeted therapies in a subset of patients harboring treatable mutations. Patients undergoing targeted therapies will also be evaluated for variations in genomic profile and radiomic signature during follow-up

NCT ID: NCT06325943 Completed - Clinical trials for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

CIDPRIT
Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

Randomized double-blind controlled study of rituximab versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) on chronic treatment with immunoglobulins. The primary objective of the study is to determine whether rituximab treatment is effective in preventing the disease from getting worse after stopping immunoglobulin treatment for six months in patients with CIDP. The secondary objective is to evaluate whether treatment with rituximab can improve the response to therapy compared to placebo in patients treated with immunoglobulins and whether it can allow to delay the mean time of worsening after discontinuation of immunoglobulin therapy. Exploratory objectives are the correlation between response to rituximab therapy and the clinical form of CIDP and the presence of antibody reactivity against node of Ranvier antigens. Intervention will be Rituximab or placebo, 1 g by intravenous infusion on day 1 and 15 after randomization and concomitant treatment for 6 months with intravenous or subcutaneous immunoglobulin at the same dosage as before randomization.

NCT ID: NCT06325735 Completed - Birth Weight Clinical Trials

Combined Systemic Inflammatory Indices and Birth Weight

Start date: December 1, 2019
Phase:
Study type: Observational

The study aimed to explore the complex relationship between various systemic inflammatory indices and birth weight

NCT ID: NCT06324851 Completed - Clinical trials for Endometrial Diseases

The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

The presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. Recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. We explored the efficacy of random started 14-day administration of Drospirenone/Estetrol or Nomegestrol Acetate/Estradiol or Ethinylestradiol/Dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy.